Evidence map›Paper›PMID 30531492›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy.

Luuk Gras, Margaret May, Lars Peter Ryder, Adam Trickey, Marie Helleberg, Niels Obel, Rodolphe Thiebaut, Jodie Guest, John Gill, Heidi Crane and 22 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05243381 (Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05243381 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2022 to 2024Enrolled60ConditionsHIV InfectionsArms20 ml blood test
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions.Journal of clinical tuberculosis and other mycobacterial diseases · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Luuk GrasStichting HIV Monitoring, Amsterdam, the Netherlands.
Margaret MayBristol Medical School, University of Bristol, Bristol, United Kingdom.
Lars Peter RyderTissue Typing Laboratory, Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Adam TrickeyBristol Medical School, University of Bristol, Bristol, United Kingdom.
Marie HellebergDepartment of Infectious Diseases, Centre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Niels ObelDepartment of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Rodolphe ThiebautINSERM, U1219 Bordeaux Population Health Research Centre, Univ. Bordeaux, INRIA SISTM, Bordeaux, France.
Jodie GuestSchool of Public Health and Emory School of Medicine, Atlanta, GA.
John GillDivision of Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
Heidi CraneCenter for AIDS Research, University of Washington, Seattle, WA.
Viviane Dias LimaBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Antonella dʼArminio MonforteClinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Milan, Italy.
Timothy R SterlingVanderbilt University School of Medicine, Nashville, TN.
Jose MiroInfectious Disease Service, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.
Santiago MorenoHospital Ramón y Cajal, Madrid, Spain.
Christoph StephanDepartment of Infectious Diseases, University Hospital Frankfurt, Goethe-University, Frankfurt am Main, Germany.
Colette SmithInstitute of Global Health, UCL, London, United Kingdom.
Janet TateDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Leah ShepherdInstitute of Global Health, UCL, London, United Kingdom.
Mike SaagDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL.
Armin RiegerUniversity of Vienna, Vienna, Austria.
Daniel GillorUniversität zu Köln, Cologne, Germany.
Matthias CavassiniService of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Marta MonteroLa Fe Hospital, Valencia, Spain.
Suzanne M IngleBristol Medical School, University of Bristol, Bristol, United Kingdom.
Peter ReissStichting HIV Monitoring, Amsterdam, the Netherlands.
Dominique CostagliolaSorbonne Universités UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (UMRS 1136), Paris, France.
Ferdinand W N M WitStichting HIV Monitoring, Amsterdam, the Netherlands.
Jonathan SterneBristol Medical School, University of Bristol, Bristol, United Kingdom.
Frank de WolfDepartment of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom.
Ronald GeskusAcademic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
Antiretroviral Therapy Cohort Collaboration (ART-CC)

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
Alcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
CIHRDepartment of Health NF-SI-0611-10168Medical Research Council G0100221Medical Research Council G0700820Medical Research Council MR/J002380/1NIAAA NIH HHS U10 AA013566NIAAA NIH HHS U24 AA020794NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI110527Wellcome TrustWellcome Trust 106680/Z/14/Z
6 · The paper itself

Abstract

backgroundAn increasing number of HIV-positive individuals now start antiretroviral therapy (ART) with high CD4 cell counts. We investigated whether this makes restoration of CD4 and CD8 cell counts and the CD4:CD8 ratio during virologically suppressive ART to median levels seen in HIV-uninfected individuals more likely and whether restoration depends on gender, age, and other individual characteristics.

methodsWe determined median and quartile reference values for CD4 and CD8 cell counts and their ratio using cross-sectional data from 2309 HIV-negative individuals. We used longitudinal measurements of 60,997 HIV-positive individuals from the Antiretroviral Therapy Cohort Collaboration in linear mixed-effects models.

resultsWhen baseline CD4 cell counts were higher, higher long-term CD4 cell counts and CD4:CD8 ratios were reached. Highest long-term CD4 cell counts were observed in middle-aged individuals. During the first 2 years, median CD8 cell counts converged toward median reference values. However, changes were small thereafter and long-term CD8 cell count levels were higher than median reference values. Median 8-year CD8 cell counts were higher when ART was started with <250 CD4 cells/mm. Median CD4:CD8 trajectories did not reach median reference values, even when ART was started at 500 cells/mm. DISCUSSION: Starting ART with a CD4 cell count of ≥500 cells/mm makes reaching median reference CD4 cell counts more likely. However, median CD4:CD8 ratio trajectories remained below the median levels of HIV-negative individuals because of persisting high CD8 cell counts. To what extent these subnormal immunological responses affect specific clinical endpoints requires further investigation.

Indexed as

CD4-CD8 RatioCD4 Lymphocyte CountCD8-Positive T-LymphocytesLymphocyte CountAdolescentAdultAnti-HIV AgentsCross-Sectional StudiesFemaleHIV-1HIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedViral LoadAnti-HIV Agents

Identifiers

PMID30531492
PMCPMC6392208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.